Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination With AMG 479 in Subjects With Advanced, Refractory Solid Tumors

NCT00819169 is registered in ClinicalTrials.gov with NantCell, Inc. as lead sponsor.

NCT NCT00819169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00819169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination With AMG 479 in Subjects With Advanced, Refractory Solid Tumors
Lead sponsor
NantCell, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
January 16, 2009
Completion date
August 10, 2011
Enrollment
89 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, locally advanced, metastatic cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, sarcoma, solid tumors